Neurocrine Biosciences
NBIX
207 hedge funds and large institutions have $3.29B invested in Neurocrine Biosciences in 2015 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 78 reducing their positions, and 23 closing their positions.
126% more call options, than puts
Call options by funds: $65M | Put options by funds: $28.8M
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
5% more funds holding
Funds holding: 198 → 207 (+9)
4% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 78
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
17% less capital invested
Capital invested by funds: $3.98B → $3.29B (-$691M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.9M |
| 2 |
CCI
Columbus Circle Investors
|
+$22.4M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
+$21.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.3M |
| 5 |
CCM
Cadian Capital Management
New York
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$82.1M |
| 2 |
O
OrbiMed
New York
|
-$61.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$49.5M |
| 4 |
PA
Perceptive Advisors
New York
|
-$16.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$16.2M |
NBIX Hedge Fund Activity: Q3 2015 in Review
207 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2015, worth a combined $3.29B — down 17% from $3.98B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new NBIX positions and 23 closed out — a net gain of 10 holders — while 81 added to existing stakes and 78 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $87.9M. The largest seller was PointState Capital, cutting an estimated $82.1M.
- 207 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2015, up from 198 in Q2 2015.
- Funds reported $3.29B of Neurocrine Biosciences stock for Q3 2015, down 17% quarter-over-quarter.
- 33 funds opened new Neurocrine Biosciences positions in Q3 2015 and 23 closed out, a net change of +10 holders.
- The largest Neurocrine Biosciences buyer in Q3 2015 was Fidelity Investments, an estimated $87.9M added.
- The largest Neurocrine Biosciences seller in Q3 2015 was PointState Capital, an estimated $82.1M sold.
Based on aggregated 13F filings for Q3 2015.